A. Brunt

Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study

Dinh Q. Phung, C. A. Shaw, M. Kumar, 2021, The Lancet Oncology.

NEAT: National Epirubicin Adjuvant Trial – toxicity, delivered dose intensity and quality of life

H. Earl, D. Rea, C. Poole, 2008, British Journal of Cancer.

Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.

H. Earl, D. Rea, S. M. Crawford, 2006, The New England journal of medicine.

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

M. Dowsett, R. Gelber, J. Baselga, 2013, The Lancet.

Economic evaluation of a standard dosage system for an outpatient breast cancer chemotherapy regimen

R. W. Fitzpatrick, A. Brunt, N. Stringer, 2001 .

Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials

C. Caldas, E. Provenzano, H. Earl, 2012, British Journal of Cancer.

Explorer Adjuvant epirubicin followed by cyclophosphamide , methotrexate and fluorouracil ( CMF ) vs CMF in early breast cancer : results with over 7 years median follow-up from the randomised phase III NEAT / BR 9601 trials

C. Caldas, E. Provenzano, P. Pharoah, 2018 .